Cooper's Own Goal: A Self-Inflicted Destock Meets a Review That Closed Where It Started

The board kept CooperSurgical after a nine-month sale process, while a proactive US channel reset masked mid-single-digit consumption and set up a 2027 rebound

COO · Earnings Call · 2026-09-09

The review that closed where it began

For most of a year, Cooper ran a sale process for CooperSurgical and let the market price in a breakup. It ended in a non-sale. “the board unanimously determined that shareholders are better served by continued ownership than by pursuing a transaction at this time” — Albert G. White, President and Chief Executive Officer · 2026-09-09 — with management attributing the gap to two temporary overhangs: a new competitive entrant in the non-hormonal IUD market and the fertility litigation settlement. This closes a strategic review that ran through Q2, Q3 and Q4 of last year, where Al White described receiving meaningful interest: “We received significant interest in the entire business and in pieces of the business” — Albert White · 2026-06-04. The setup is somewhat awkward — in December he had said of the valuation “I look at where our valuation is today, which I believe is absurd” — Albert White · 2026-06-04, and the stock is lower now than it was when he said it (down 44% from its 2021 peak, and about 17% off its August high). The pivot is explicit: capital and attention rotate hard toward CooperVision organic growth, with fertility a distant second. Read across the two businesses together is out; fix Vision execution is in.

The destock nobody ordered from the market

The headline revenue miss is entirely self-inflicted. Channel inventory is the quarter's top company keyword — brand-new as the #1 slot — and White is blunt: “it's all destock… the entire reason for the reduction in the revenue guidance for CooperVision was tied to just channel inventory. That's it.” — Albert G. White, President and Chief Executive Officer · 2026-09-09 Americas would have grown ~5% absent the reset, while US consumption ran mid-single digits. He walks through the why in detail — distributors stocking ahead of price increases, consolidation, IT upgrades, and most recently contracts won — and decided to burn the overhang now rather than let it drag 2027: “rather than doing that… we decided to go ahead and proactively accelerate that and just get that taken care of right now in Q3 and Q4” — Albert G. White, President and Chief Executive Officer · 2026-09-09. But channel inventory is not a new Cooper theme — it's a recurring one. In the Q2 2025 call White said: “I think that we're just gonna continue to get pressure as we move through this year from inventory levels on a year over year basis” — Al White, President and Chief Executive Officer · 2025-05-29. What's different this time is agency: management is choosing the magnitude and timing, and ring-fencing it. Watch the interplay with legacy hydrogel rationalization, which is also ending in Q4 and has been a multi-quarter drag. And the second new theme is people: sales force expansion of roughly 5,000 incremental doors, with new reps landing on the street late in fiscal Q2 2027.

We don't have a manufacturing issue… We don't have a distribution or logistics issue. We don't have a problem winning contracts… Where we've struggled is execution at the end of that… We don't have enough salespeople out there. Like, hindsight's 20/20. We should have moved faster on this.
Albert G. White, President and Chief Executive Officer · 2026-09-09

That is the clearest articulation yet of what's actually wrong with CooperVision, and it's a diagnosis the company can act on.

Record cash, shrinking float, and the market's response

The offsetting story is cash. Cooper printed its best-ever quarterly free cash flow — $273M, with fiscal year-to-date free cash flow of $528M, up 86% year over year — and management reaffirmed the $2.2B FY26–28 cumulative target. It works because the balance sheet is still levered: effective net cash of roughly -$2.3B. Against a price-to-FCF of ~24x, the board added $1B to the repurchase authorization, lifting remaining capacity to ~$1.5B, and bought $339M in the quarter. This was the promised pivot: “we do not have those restrictions now and would anticipate exiting this call being much more aggressive on share buybacks going forward” — Albert White · 2026-06-04. A ~$307M discrete HMRC tax benefit adds low-tax-rate visibility for at least a decade.

Reading it against the tape

The GAAP optics look terrible — the latest filed quarter shows operating margin of -4.5% — but that reflects non-recurring charges, not the underlying ~26% non-GAAP margin run rate. The market isn't rewarding much of this yet: the stock is essentially flat over 90 days. One genuine cross-sectional tie-in: Tariff Refund was the global market's #1 keyword last quarter, and it echoed across peers this earnings season (AEO, ASO, JILL, SIG). Cooper's own ~$0.03 EPS tariff benefit is a rounding error by comparison — but it signals that the refund/rebate cycle is a real, shared cash tailwind the market is trading on. Net: a mid-cap medical-device name that delivered record cash, chose to take a revenue haircut on its own terms, and just closed a breakup thesis without a breakup. The next leg is entirely about whether the sales-force bet converts MyDay and MiSight demand into revenue. As White put it, "one more box we need to check."